Piha-Paul, Sarina A. http://orcid.org/0000-0001-9455-1660
Tseng, Chieh
Leung, Cheuk Hong http://orcid.org/0000-0002-2531-7739
Yuan, Ying
Karp, Daniel D.
Subbiah, Vivek http://orcid.org/0000-0002-6064-6837
Hong, David
Fu, Siqing
Naing, Aung http://orcid.org/0000-0002-4803-8513
Rodon, Jordi
Javle, Milind
Ajani, Jaffer A. http://orcid.org/0000-0001-9946-0629
Raghav, Kanwal P. http://orcid.org/0000-0003-1311-4173
Somaiah, Neeta
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Tsimberidou, Apostolia M. http://orcid.org/0000-0003-2713-233X
Zheng, Xiaofeng
Chen, Ken http://orcid.org/0000-0003-4013-5279
Meric-Bernstam, Funda http://orcid.org/0000-0001-6816-6072
Article History
Received: 25 August 2023
Accepted: 9 July 2024
First Online: 31 July 2024
Competing interests
: SPP reports clinical trial research funding/grant support through the institution from AbbVie, Inc.; ABM Therapeutics, Inc.; Acepodia, Inc; Alkermes; Aminex Therapeutics; BioMarin Pharmaceutical, Inc; Boehringer Ingelheim; Bristol Myers Squib; Cerulean Pharma, Inc.; Chugai Pharmaceutical Co., Ltd; Curis, Inc.; Cyclacel Pharmaceuticals; Daiichi Sankyo; Eli Lilly; ENB Therapeutics; Epigenetix Inc.; Five Prime Therapeutics; F-Star Beta Limited; F-Star Therapeutics; Gene Quantum; Genmab A/S; Gilead Sciences, Inc.; GlaxoSmithKline; Helix BioPharma Corp.; Hengrui Pharmaceuticals, Co., Ltd.; HiberCell, Inc.; Immorna Biotherapeutics, Inc.; Immunomedics, Inc.; Incyte Corp.; Jacobio Pharmaceuticals Co., Ltd.; Jiangsu Simcere Pharmaceutical Co., Ltd.; Loxo Oncology, Inc.; Lytix Biopharma AS; Medimmune, LLC.; Medivation, Inc.; Merck Sharp and Dohme Corp.; Nectin Therapeutics, Ltd.; Novartis Pharmaceuticals; Nurix; Pieris Pharmaceuticals, Inc.; Pfizer; Phanes Therapeutics; Principia Biopharma, Inc.; Puma Biotechnology, Inc.; Purinomia Biotech, Inc.; Rapt Therapeutics, Inc.; Replimune; Roche/Blueprint; Seattle Genetics; Silverback Therapeutics; Shasqi, Inc.; Synlogic Therapeutics; Taiho Oncology; Tesaro, Inc.; Theradex Oncology; Toragen Therapeutics, Inc.; TransThera Bio; Xencor, Inc; ZielBio, Inc.;NCI/NIH; P30CA016672 – Core Grant (CCSG Shared Resources). CHK reports research funding from NIH/NCI P30CA016672 and Biostatistics Resource Group. YY served as a statistical consultant to AbbVie, Amgen, Bexion, BeyondSpring, Boehringer Ingelheim, Bristol Myers Squibb, Century, Enliven, GT Medical, NeoImmueTech, Merck, NGM, Repare, Servier, Starpax, Transthera, Xinthera, and Vertex. DDK reports research funding/grant support for clinical trials from Pfizer, Phoplatin Therapeutic, Symphogen, NIH clinical translation science award, clinical translation NCI grant and consultancy/advisory board participation for Black Beret Life Science, Affigen and Phosplatin. VS reports research funding/grant support for clinical trials from AbbVie, Agensys, Inc., Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines Corporation, Boston Biomedical, Inc., Boston Pharmaceuticals, Celgene Corporation, D3 Bio, Inc., Dragonfly Therapeutics, Inc., Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Inc., Incyte Corporation, Inhibrx, Loxo Oncology, MedImmune, MultiVir, Inc., NanoCarrier, Co., National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics, UT MD Anderson Cancer Center, and Vegenics Pty Ltd.; travel support from ASCO, ESMO, Helsinn Healthcare, Incyte Corporation, Novartis, and PharmaMar; consultancy/advisory board participation for Helsinn Healthcare, Jazz Pharmaceuticals,Incyte Corporation, Loxo Oncology/Eli Lilly, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics, Daiichi-Sankyo, and R-Pharm US; and other relationship with Medscape. DH reports research funding/grant support for clinical trials from AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astra-Zeneca, Bayer, Biomea, Bristol-Myers Squibb, Daiichi-Sankyo, Deciphera, Eisai, Eli Lilly, Endeavor, Erasca, F. Hoffmann-LaRoche, Fate Therapeutics, Genentech, Genmab, Immunogenesis, Infinity, Kyowa Kirin, Merck, Mirati, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, Revolution Medicine, SeaGen, STCube, Takeda, TCR2, Turning Point Therapeutics, VM Oncology. Also received t<i>ravel, Accommodations, Expenses from</i> AACR, ASCO, CLCC, Bayer, Genmab, SITC, Telperian and serves as <i>consulting, Speaker, or Advisory Role for</i> 28Bio, Abbvie, Acuta, Adaptimmune, Alkermes, Alpha Insights, Amgen, Affini-T, Astellas, Aumbiosciences, Axiom, Baxter, Bayer, Boxer Capital, BridgeBio, CARSgen, CLCC, COG, COR2ed, Cowen, Ecor1, EDDC, Erasca, Exelixis, Fate Therapeutics, F.Hoffmann-La Roche, Genentech, Gennao Bio, Gilead, GLG, Group H, Guidepoint, HCW Precision Oncology, Immunogenesis, Incyte Inc, Inhibrix Inc, InduPro, Janssen, Jounce Therapeutics Inc, Liberium, MedaCorp, Medscape, Novartis, Numab, Oncologia Brasil, ORI Capital, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, Projects in Knowledge, Quanta, RAIN, Ridgeline, SeaGen, Stanford, STCube, Takeda, Tavistock, Trieza Therapeutics, Turning Point Therapeutics, WebMD, YingLing Pharma, Ziopharm. DH also reports Other ownership interests: Molecular Match (Advisor), OncoResponse (Founder, Advisor), Telperian (Founder, Advisor). SQF reports research funding/grant support for clinical trials from NIH/NCI P30CA016672 – Core Grant (CCSG Shared Resources); Abbisko; BeiGene; BioAtla, LLC.; Boehringer Ingelheim; CUE Biopharma, Inc.; Eli Lilly & Co.; Exelixis; Greenfire Bio, Inc.; Hookipa Biotech; IMV, Inc.; Innovent Biologics, Co., Ltd.; K-Group Beta; Lyvgen Biopharm, Co., Ltd.; MacroGenics; MediLink Therapeutics, Co. Ltd.; Millennium Pharmaceuticals, Inc.; Nerviano Medical Sciences; NeuPharma, Inc.; NextCure, Inc.; Ningbo NewBay Technology Development Co., Ltd.; Novartis; NovoCure; Nykode Therapeutics AS.; Parexel International, LLC; Pionyr Immunotherapeutics, Inc.; PureTech Health, LLC; Sellas Life Sciences Group; Soricimed Biopharma, Inc.; SQZ Biotechnologies; Sumitomo Dainippon; Taiho Oncology and NCCN; Treadwell Therapeutics; Turnstone Biologics; Tyligand Bioscience, Ltd.; Virogin Biotech, Ltd. AN reports research funding/grant support for clinical trials from NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor/Millendo, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, Immune-Onc Therapeutics, Surface Oncology, Monopteros Therapeutics, BioNTech SE, Seven & Eight Biopharma, and SOTIO Biotech AG. Consulting fees from CTI, Deka Biosciences, Janssen Biotech, NGM Bio, PsiOxus Therapeutics, Immune-Onc Therapeutics, STCube Pharmaceuticals, OncoSec KEYNOTE-695, Genome & Company, CytomX Therapeutics, Nouscom, Merck Sharp & Dohme Corp, Servier, Lynx Health, AbbVie, PsiOxus. AN received travel and accommodation expense from ARMO BioSciences, NeoImmuneTech, NGM Biopharmaceuticals and honoraria for speaking engagement from AKH Inc, The Lynx Group, Society for Immunotherapy of Cancer (SITC), Korean Society of Medical Oncology (KSMO), Scripps Cancer Care Symposium, ASCO Direct Oncology Highlights, European Society for Medical Oncology (ESMO), CME Outfitters. JR reports non-financial support and reasonable reimbursement for travel from European Society for Medical Oncology; receiving consulting and travel fees from Ellipses Pharma and IONCTURA (including serving on the scientific advisory board); Consulting fees from Aadi Bioscience, Clarion Healthcare, Debiopharm, Monte Rosa Therapeutics, Cullgen. Pfizer, Merus N.V., Macorgenics, Oncology One, Envision Pharma, Columbus Venture Partners, Sardona Therapeutics, Avoro Capital Advisors, Vall d’Hebron Institute of Oncology/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, Boxer Capital, LLC, Tang Advisors, LLC, Incyte, Alnylam Pharmaceuticals ; receiving research funding from Blueprint Medicines, Black Diamond Therapeutics, Merck Sharp & Dohme, Hummingbird, Yingli and Vall d’Hebron Institute of Oncology/Cancer Core Europe; and serving as investigator in clinical trials with Novartis, Spectrum Pharmaceuticals, Symphogen, BioAlta, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GalxoSmithKline, Taiho, Roche Pharmaceuticals, Hummingbird, Yingli, Bycicle Therapeutics, Merus, Curis, Bayer, AadiBioscience, Nuvation, ForeBio, BioMed Valley Discoveries, Loxo Oncology, Hutchinson MediPharma, Cellestia, Deciphera, Ideaya, Amgen, Tango Therapeutics, Mirati, Linnaeus Therapeutics, and Cancer Core Europe. MJ reports grants from QED, personal fees from Incyte, grants from Taiho, other from Novartis, personal fees from Oncosil, grants and personal fees from MERCK, grants from EMD SERONO, personal fees and non-financial support from MECLUN, outside the submitted work. JA serves as ad hoc paid advisor to: BMS, Merck, Astellas, Daiichi, Zymeworks, Jazz, Novartis, Gilead, Taiho, Amgen. KR reports research funding/grant support from AbbVie, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Genentech, Guardant Health, HiberCell, Innovent, Janssen, Merck, Seattle Genetics, UCB Biosciences, Xencor and serves as consultant for AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Genentech, Seattle Genetics. NS reports current clinical trial research funding/grant support through the institution from AstraZeneca, Innovent, Ascentage, Deciphera, Boehringer Ingelheim, and Advisory Board consultant for Aadi Biosciences, Bayer, and Boehringer Ingelheim. GBM reports SAB/Consultant: Amphista, Astex, AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, GSK, ImmunoMET, Infinity, Ionis, Leapfrog Bio, Lilly, Medacorp, Nanostring, Nuvectis, PDX Pharmaceuticals, Qureator, Roche, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals; Stock/Options/Financial: Bluedot, Catena Pharmaceuticals, ImmunoMet, Nuvectis, SignalChem, Tarveda, Turbine; Licensed Technology: HRD assay to Myriad Genetics, DSP patents with Nanostring; Sponsored research: AstraZeneca. AT reports research funding/grant support for clinical trials from OBI Pharma USA Inc., Baxalta, Bayer, Boston Biomedical, Cancer Prevention & Research Institute of Texas (CPRIT), EMD Serono, IMMATICS, Parker Institute for Cancer Immunotherapy, Placon Therapeutics, Agenus, Tachyon, Tempus Labs, Tvardi Therapeutics, Karus Therapeutics; Novocure Ltd., Orionis, NIH/NCI P30CA016672 – Core Grant (CCSG Shared Resources). AT served as consulting or advisory role for Vincerx, BrYet, and Diaccurate, NEX-I, Macrogenics, Avstera. FM-B reports research funding/grant support for clinical trials from Aileron Therapeutics, AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences, Curis, CytomX Therapeutics, Daiichi Sankyo, Debiopharm International, eFFECTOR Therapeutics, Genentech, Guardant Health, Klus Pharma, Takeda Pharmaceutical, Novartis, Puma Biotechnology, Taiho Pharmaceutical. FM-B served as advisory committee for Black Diamond, Biovica, Eisai, FogPharma, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Sanofi, Silverback Therapeutics, Spectrum Pharmaceuticals, Zentalis, personal fees for consulting/travel related from AbbVie, Aduro BioTech, Alkermes, AstraZeneca, Daiichi Sankyo, DebioPharm, Ecor1 Capital, eFFECTOR Therapeutics, F. Hoffman-La Roche, GT Apeiron, Genentech, Harbinger Health, IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, Menarini Group, OrigiMed, PACT Pharma, Parexel International, Pfizer, Protai Bio, Samsung Bioepis, Seattle Genetics, Tallac Therapeutics, Tyra Biosciences, Xencor, Zymeworks, European Organization for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), personal fees for honoraria from Chugai Biopharmaceuticals. No potential conflicts of interest were disclosed by the other authors.